| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate o...
Allen Institute to employ Iterative Mapping, Nautilus' single-molecule proteomics method, to investigate connection between...